TOI 8-K: SEC filing

Filed with the SEC on · accession 0001079973-26-001457

TOI filed a 8-K (current report) with the SEC on Nov 12, 2026. Starling Oncology, Inc. furnished an investor presentation dated November 12, 2026 under Regulation FD Disclosure (Item 7.01) via a Form 8-K.

Summary of the filing

Starling Oncology, Inc. furnished an investor presentation dated November 12, 2026 under Regulation FD Disclosure (Item 7.01) via a Form 8-K. The presentation is for use in meetings with investors and is furnished, not filed, for Exchange Act purposes.

Key details

RegistrantStarling Oncology, Inc.
Chief legal officerMinh Merchant

✦ Ask GOAX AI about this filing — what it means for TOI, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for TOI?

Click here

Frequently asked questions

What did TOI file with the SEC on Nov 12, 2026?

TOI filed a 8-K (SEC filing). Starling Oncology, Inc. furnished an investor presentation dated November 12, 2026 under Regulation FD Disclosure (Item 7.01) via a Form 8-K. The presentation is for use in meetings with investors and is furnished, not filed, for Exchange Act purposes.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other TOI SEC filings

Get alerts when TOI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days